Egypt. J. Chem. Vol. 67, SI: M. R. Mahran, pp. **1373 - 1386** (2024)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Biochemical Basis of Inflammatory Response in Nursing: Implications for Patient Care and Treatment

Seham Abdu Hussain Althurwi[1], Fahdah Fahad Alanazi[2], Mona Ahmed Kariri[2], Bdoor Hassan Alenzie[3], Abdullah Duwayhim Abdullh[4], Bairum Ibrahim Khairi[5], Fatimah Saeed Al Shahrany[6], Lulua Mohammed Alateiwi[7], Khulud Shaya Salem Alqahtani[8], Jawaher Mnwer Alrashedi[8], Salma Ali Hassan Magbol[9], Wafa Saad Alharthi[8], Montaha Ali Shatti Alshammari[8], Ayat Ibrahim Zaidan[9], Nuha Falah Alharbi[7]

1 Alaidabi General Hospital, Ministry of Health, Saudi Arabia
2 First Health Cluster, Ministry of Health, Saudi Arabia
3 The first health cluster in Riyadh, Primary Health Care Center in Saudi District, Al Kharj, Ministry of Health, Saudi Arabia
4 Riyadh First Health Cluster, Ministry of Health, Saudi Arabia
5 Jazan Health Cluster, Ministry of Health, Saudi Arabia
6 Thired health cluster, Ministry of Health, Saudi Arabia
7 Aljazeerah PHC-Riyadh 2nd cluster, Ministry of Health, Saudi Arabia
8 Ministry of Health branch in Riyadh, Ministry of Health, Saudi Arabia
9 Jazan Health Cluster, Ministry of Health, Saudi Arabia.

Abstract

Background: Inflammation is a fundamental immune response that defends the body against injury and infection. However, chronic inflammation is linked to various pathological conditions, including autoimmune disorders and cardiovascular diseases. The biochemical mechanisms underpinning inflammation involve multiple signaling pathways and mediators, each contributing to the body's immune and healing processes. Nursing professionals are integral to managing inflammatory disorders, bridging biochemical knowledge with clinical care to enhance patient outcomes.

Aim: This article aims to analyze the biochemical basis of inflammation, emphasizing the role of nursing in managing inflammatory responses through an understanding of cellular signaling and mediators. The goal is to provide insight into how nursing practices can mitigate inflammation's adverse effects and promote effective patient care.

Methods: A review of current literature was conducted, focusing on the biochemical pathways involved in inflammation and the role of nursing in inflammatory disorder management. The study covers three principal signaling pathways: the NFκB pathway, Mitogen-Activated Protein Kinase (MAPK) pathway, and Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway, along with other key inflammatory mediators, including the kinin system, free radicals, histamine, and cell adhesion molecules.

Results: The study finds that the NFκB, MAPK, and JAK-STAT pathways play a crucial role in regulating inflammatory responses. Inflammatory mediators like histamine and free radicals contribute to the progression of inflammation, and their dysregulation can exacerbate chronic inflammatory conditions. Nurses' understanding of these pathways enables early intervention, improved patient monitoring, and effective symptom management, which are essential for reducing inflammation and preventing complications.

Conclusion: An in-depth knowledge of the biochemical aspects of inflammation allows nursing professionals to better assess and manage inflammatory disorders, aligning therapeutic interventions with the underlying molecular processes. By incorporating biochemical insights into patient care, nurses can optimize treatment outcomes and contribute to the holistic management of inflammation-related disorders. Further training in biochemical mechanisms is recommended to strengthen nursing practices and patient care standards

Keywords: Inflammation, Nursing, NFκB pathway, MAPK pathway, JAK-STAT pathway, Inflammatory mediators, Patient care, Biochemical mechanism.

1. Introduction

Diseases caused by inflammatory processes pose the greatest threat to human health, according to the World Health Organization (WHO). They are the primary causes of death worldwide and are expected to overtake all other causes of death in the US in the next thirty years. Approximately 60% of Americans have at least one chronic inflammatory disease, according to a 2014 Rand Corporation research [1], [2], and [3-5]. A defensive physiological reaction brought on by damaging stimuli, inflammation aids in

*Corresponding author e-mail: saalthurwi@moh.gov.sa.; (Seham Abdu Hussain Althurwi).
Receive Date: 13 November 2024, Revise Date: 25 November 2024, Accept Date: 01 December 2024
DOI: 10.21608/ejchem.2024.336228.10798

the removal of pathogens, the healing of injured tissue, and the return of homeostasis [3]. Numerous things, such as tissue damage, autoimmune reactions, or microbial, viral, or fungal infections, can trigger the inflammatory response. Due to immunological, biochemical, and physiological changes that cause the production of pro-inflammatory mediators at the site of damage, these processes lead to the typical symptoms of redness, swelling, heat, pain, and loss of function. Leukocyte recruitment, vascular permeability, and blood flow are all increased by these mediators [4, 5, 6].

Inflammatory mediators, such as chemokines, cytokines, vasoactive amines, eicosanoids, and proteolytic cascade products, are responsible for the cellular and vascular processes that define the inflammatory process [7]. Local cells at the site of inflammation generate these mediators, or the liver produces them as inactive precursors that travel through the blood plasma and become active when they come into touch with certain receptors at the site of injury [8]. While certain mediators, like nitric oxide, cause oxidative damage, others, like proteases, directly affect enzyme activity [9], [10]. In addition to producing newly synthesized mediators during the inflammatory process, such as prostaglandins, leukotrienes, platelet-activating factor, reactive oxygen species, nitric oxide, and cytokines, immune cells can also store pre-synthesized mediators, such as histamine, serotonin, and lysosomal enzymes, in granules. Furthermore, the liver generates mediators that trigger the kinin and complement systems, which in turn promote thrombosis, inflammation, chemotaxis, and vascular leakage [11]. Numerous illnesses, including multiple sclerosis and Alzheimer's disease, are linked to inflammatory processes, many of which have poorly known mechanisms [12], [13]. Prolonged and low-grade inflammation can weaken the blood-brain barrier in certain neurodegenerative diseases, which increases the influx of immune cells and pro-inflammatory cytokines into brain tissue. Microglial dysfunction brought on by this disturbance may hinder the brain's capacity to carry out neuroprotective processes [14]. In this sense, investigations into the molecular processes that underlie inflammation provide insightful information from a variety of angles and merit more study.

General Overview of Inflammation

When tissue is damaged, endothelial cells in blood vessel walls become activated, starting the inflammatory response. Phospholipids in the plasma membrane are broken down enzymatically by epithelial cells in the injured tissue, producing arachidonic acid in the process. Pro-inflammatory chemicals such prostaglandins and leukotrienes are produced as a result of this mechanism [15]. Changes in blood artery diameter and flow are the first vascular impacts of inflammation. These changes are caused by pro-inflammatory chemicals such mast cell-produced histamine and endothelial nitric oxide, which is created at different rates based on the severity of the cellular injury. The arterioles first experience a brief period of vasoconstriction, which is followed by vasodilation [16]. The strength of the stimulus determines how long vasodilation lasts [17]. Transudation, or the extravasation of capillary fluid into the tissue, is caused by arterial vasodilation, which raises the hydrostatic pressure between arteries as blood flow increases. The increased vascular permeability brought on by histamine, kinins, and other mediators, which quickly create spaces between endothelial cells, surpasses this process [18]. Moreover, edema is caused by leukocytes and protein-rich fluid (exudate) entering the inflammatory site due to enhanced vascular permeability [19]. Leukocyte migration and activation at the site of damage, triggered by cellular processes, is a crucial aspect of the inflammatory process [20]. At the extravascular space and endothelial interface, leukocyte recruitment entails a number of processes, such as migration, rolling adhesion, firm adhesion, transmigration, and marginalization. Adhesion molecules found on the membrane of endothelial cells, such as selectins and integrin ligands, at least partially control these processes. Furthermore, leukocyte localization to the damaged region is facilitated by interactions between integrins and their ligands (chemokines), which encourage phagocytosis [21].

Cellular Signaling of Inflammatory Pathways

Despite the fact that the processes behind inflammation differ based on the type of inflammatory agent, they always come together on a common innate immune response pathway. The first step in this process is the activation of pattern-recognition receptors (PRRs) on the cell surface that are encoded by germlines and are capable of detecting damaging stimuli [6, 22, 23]. By interacting with PRRs expressed on immune and non-immune cells, microbial structures known as pathogen-associated molecular patterns (PAMPs) set off intracellular processes that stimulate the immune system and start the inflammatory response [6, 24, 25]. Certain PRRs

can also identify danger-associated molecular patterns (DAMPs), which are endogenous signals produced during tissue or cellular injury. Even when there are no infectious organisms present, these biomolecules can promote the synthesis of mediators like cytokines. Roh and Hyun (2018) claim that the NF-κB pathway can also be activated during stress to create these substances. retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs), and Toll-like receptors (TLRs) are the families of PRRs. Ten different proteins that are either found on the cell membrane or inside endosomes and contribute to the inflammatory response's activation make up the TLR family [26]. The transcription of genes implicated in the inflammatory response is promoted by PRRs' recognition of PAMPs or DAMPs, with the exception of certain NLRs. These genes encode proteins that affect PRR signaling, chemokines, pro-inflammatory cytokines, and type I interferons (IFNs), according to Shekarian et al. (2018).

The identification of lipopolysaccharides (LPS) and PAMP flagellin (mostly by TLR4 and TLR5) on the cell membrane is how PAMPs and PRRs interact through these molecules. While NLRs and RLRs identify PAMPs and DAMPs at the cytoplasmic level, recognition can also take place through endosome-expressed TLR3, TLR7, TLR8, and TLR10 [27]. In the case of DAMPs, their function is closely related to where they are recognized. These interactions trigger the adaptive immune response, control immunological responses, and promote signal transduction in the context of inflammation. In addition to secreting pro-inflammatory substances like TNF-α, IL-1, IL-6, and cytokines (IL-4, IL-10, IL-12, and IL-18), they are in charge of attracting neutrophils and macrophages. These elements play a key role in the pathogenesis of diseases such as multiple sclerosis, which are characterized by an overreaction to inflammation [27]. Myeloid differentiation factor-88 (MyD88), a cytosolic adaptor protein that controls TLR signaling, mediates the transmission of PAMPs and DAMPs. As a result, TLR signaling triggers intracellular signaling cascades, which in turn cause different transcription factors to translocate (**Fig. 1**) [6], [28]. By interacting with their respective receptors, TLRs, IL-1 receptor (IL-1R), IL-6 receptor (IL-6R), and TNF receptor (TNFR), microbial products and cytokines—in particular, IL-1β, IL-6, and TNF-α—act as the main inflammatory stimuli during this process [6], [29]. The activation of nuclear factor kappa-B (NF-κB), Janus kinase (JAK), mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription (STAT) pathways via different adaptor proteins facilitates the spread of signals. By activating interferon regulatory factors (IRFs), this cascade results in the generation of interferons and inflammatory cytokines [30].



Figure 1: Intracellular signaling via Toll like receptors (TLRS).

NFκB Pathway (Nuclear Factor Kappa B):

The five transcription factors that make up the protein complex known as NFκB are p50, p52, RelA (p65), RelB, and c-Rel in mammals. Lawrence (2009) points out that this complex is essential for many biological and cellular processes. It can be activated through the canonical pathway, which is usually triggered by pro-inflammatory cytokines like TNFα and IL-1 and microbial components, or through the alternative pathway, which is stimulated by TNF family cytokines like β-lymphotoxin (TNFSF3), CD40 ligand (CD40L, TNFSF5), B-cell activating factor (BAFF, TNFSF13B), and receptor activator of NFκB ligand (RANKL, TNFSF11). [31]. IKB phosphorylation (IKK), which involves the regulatory protein NEMO and catalytic kinase subunits IKKα and IKKβ, takes place upon cellular activation. A wide range of gene expression is triggered when NF-κB heterodimers are released from the NF-κB/IκB complex and translocated to the nucleus (**Fig. 2**). [6], [32].



Figure 2: Canonical and alternative pathways of the NF-κB pathway.

Mitogen-Activated Protein Kinase (MAPK) Pathway:

MAPK cascades are essential signaling pathways that regulate cellular processes like differentiation, death, proliferation, and reactions to stressors. Inflammatory and autoimmune diseases are linked to disruptions in these pathways [33]. The four subfamilies of MAPKs include p38 MAPKs (p38α, p38β, p38γ, p38δ), c-Jun N-terminal kinases (JNK1, JNK2, JNK3), extracellular signal-regulated protein kinases (ERK1 and ERK2), and ERK5 (BMK) [34]. MAPK Kinase Kinase (MAPKKKs), MAPK kinase (MAPKKs), and MAPKs are the three key kinases involved in each pathway. Through phosphorylation, MAPKKKs trigger MAPKKs, which trigger MAPKs. JNK and p38 are normally triggered by inflammatory stimuli and stress, whereas ERKs are usually triggered by mitogens and differentiation signals. MKK4 and MKK7 engage JNK, MKK3 and MKK6 engage p38, while MKK1 and MKK2 engage ERK1/2. The inflammatory response is started when MAPKs, such as ERK1/2 and JNK, are activated. This causes transcription factors in the cytoplasm or nucleus to become phosphorylated and activated (**Fig. 3**) [6], [34], and [35].



Figure 3: MAPK Signaling Pathway. Created with Biorender (2023).

JAK-STAT (Janus Kinase) Pathway:

Tyrosine kinase-linked receptors (JAK and STAT) are involved in the JAK/STAT signaling pathway, which is essential for immunological control and other cellular functions. Ruan et al. (2019) state that phosphorylation of the corresponding JAK tyrosine kinases is triggered by receptor activation by ligands such as growth factors, granulocyte-macrophage colony-stimulating factor (GM-CSF), cytokines (IL-2, IL-7), and interferon [36]. Each of the seven homologous JAK (JH) domains that make up the JAK family—JAK-1, JAK-2, JAK-3, and TyK-2—has a kinase domain (JH-1), and receptor-binding domains (JH-6 and JH-7). STAT1–4, STAT5b, and STAT6 are among the STAT family proteins that are recruited and phosphorylated by the JAK tyrosine kinase fragment. STATs enter the nucleus after activation, attach to particular gene sequences, and affect the production of different proteins, including those implicated in inflammation [37]. The pathophysiology of many inflammatory, immunological, metabolic, and cancer-related disorders is linked to these pathways. The transcription of genes involved in the expression of cytokines, tumor and growth factors, chemokines, and eicosanoids results from their activation, which is a complicated process mediated by a number of variables. Addressing inflammatory disease disorders requires an understanding of these pathways.

Inflammatory Mediators:

Inflammatory mediators, specifically cytokines and chemokines, function as essential elements of the host's innate immune response. This mechanism evolved to efficiently expel infectious agents, leverages various biomarkers, cytokines, and chemokines to promote repair and immune response (Lawrence, 2009)es are a crucial class of proteins involved in inflammation and are produced by diverse

cell types to modulate innate and adaptive immune responses. For instance, several cytokines stimulate bone marrow progenitors to enhance leukocyte production, thus supporting immune response continuity. The term "interleukins" denotes their unique function in facilitating interactions among leukocytes. CytokinIL-1 (produced by macrophages and epithelial cells), IL-2 (from T cells), IL-4 (Th2 cells and mast cells), IL-6 (T cells, macrophages), IL-9, IL-10, IL-12, IL-13, IL-17, IL-18, IL-31, IL-33, and Interferon-γ from Th1 cells . Within the inflamonse, cytokines can be categorized into pro-inflammatory (e.g., IL-1, TNF, IL-6) and anti-inflammatory (e.g., IL-4, IL-10, IL-13) groups, where macrophages produce pro-inflammatory cytokines and T cells release anti-inflammatory cytokines to regulate immune responses . Among the cytokines is a s as chemokines, responsible for directing leukocyte movement toward inflammation sites, thus regulating cell migration dynamics. Chemokines include MCP-1, MIP-1α, MIP-1β, IL-8, MIG, IP-10, and BLC, produced by macrophages, dendritic cells, and epithelial cells, among others . These chemokines are classified based disulfide linkages, which define four subfamilies: α (CXC), β (CC), δ (CX3C), and γ (XC). Each subgroup exhibits distinct roles in immune responses. For instance, α or CXC chemokines often initiate inflammatory responses, while β chemokines are implicated in chronic or allergic inflammation . These chemokines engage with G protein-coupled classified into α (CXCR), β (CCR), δ (CX3CR), and γ (XCR), to trigger intracellular signaling pathways that drive immune responses.

Key pro-inflammatory cytokines, TNF-α and IL-1, are fund inflammation, as they contribute to both acute and chronic inflammation. TNF-α has two receptors: TNF-R1, present across cell types and associated with apoptotic pathways, and TNF-R2, found mainly in hematopoietic cells, involved in cellular survival without initiating apoptosis. The interaction between TNF-α and TNF-R1 has shown potential in promoting invasive properties in cancer cells, such as pancreatic cancer, while IL-1β is known to enhance tumor cell migration in pancreatic tissue . Additionally, TNF-α and IL-1 are linked to renal inflammation and co tissue damage during urinary obstruction through the recruitment of immune cells . In infectious diseases such as dengue, the immune response involves cytokine TNF-α, IL-2, IL-6, and IFN-γ in early stages, followed by IL-10, IL-5, and IL-4 in later stages. The cytokines, associated with Th1 and Th2 responses, facilitate communication between immune cells, particularly monocytes and macrophages, indicating the body's response to viral infection . Studies indicate that chemokines play a pivotal role in natural immunity against bacteens, facilitating leukocyte mobilization to infection sites, thereby containing bacterial spread. For instance, *Mycobacterium tuberculosis* induces chemokine expression through interactions between T cells and macrophages. This results in the production of chemokines such as CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 by human macrophages, promoting bacterial clearance and granuloma formation, a critical response to prevent disease progression . The role of chemokines differs in viral infections, highlighting their versatile functions in immion [38-48].

The Kinin System:

During blood coagulation, some active molecules are essential for starting the inflammatory response. One of these molecules is the Hageman factor (factor XII), a protein produced in the liver that is involved in the coagulation cascade and can be found in collagen or platelets in either an active or inactive form [49]. The kinin system, which produces important mediators for the inflammatory response, activates the Hageman factor during inflammation. Kininogens are the plasma proteins that produce these peptides [50]. Both plasma and tissue pathways produce kinins during the inflammatory response, and plasma activation happens separately from tissue pathways. Activated factor XII and pre-kallikrein, a high molecular weight kininogen, combine to initiate the plasma activation pathway. Pre-kallikrein is changed into kallikrein upon activation of factor XII, which in turn activates factor XII to XIIa. Bradykinin is eventually released by this cascade [51]. A physiological peptide of the kinin group called bradykinin causes vasodilation, which lowers blood pressure. Similar to histamine, it promotes smooth muscle contraction, hyperalgesia, vasodilation, and enhanced vascular permeability [52], [53]. Interestingly, bradykinin is an inflammatory signal that causes swelling, heat, and redness—three of the five traditional indicators of inflammation. Kinin receptors on nociceptive nerve endings interact to produce pain, the fourth sign [11].

Depending on the receptor signaling and its expression in endothelial and smooth muscle cells, activated kinins can produce vasodilation or vasoconstriction, inflammation, and the attraction of neutrophils. Additionally, kinins have a major role in thrombotic events, microbial removal, and cell debris

clearance through their interactions with the Complement and Renin-Angiotensin Systems (RAS) [11]. The constitutively expressed kinin 2 receptor (B2R) and the inducible kinin 1 receptor (B1R) are the two primary receptors via which kinins operate in inflammatory microenvironments [54]. Bradykinin (BK) and Lys-BK peptides are highly favored by B2R, which is found in both central and peripheral organs. On the other hand, B1R, which is typically expressed at low levels, has a high affinity for certain metabolites and rapidly increases expression in response to cytokine release, cell damage, or inflammatory stimuli—conditions that are strongly associated with a number of neoplasias [55], [56]. Because of their mitogenic effects and capacity to activate tyrosine and MAP kinases, which may affect tumor growth and migration, recent research points to a function for kinins and their receptors in cancer [57]. In breast cancer cell lines such as MCF-7 and ZR 75-1, for instance, B1R activation promotes cell proliferation by triggering extracellular signal-regulated kinases, which in turn release matrix-degrading enzymes MMP2 and MMP9 [60]. Similarly, B2R activation encourages proliferation in PC3 and other cancer cell lines, but B1R inhibition in PC3 decreases cell growth in vitro [61]. Studies on bladder cancer have shown that B1R and B2R receptors promote the growth of cancer cells, but that receptor antagonists can inhibit this growth, suggesting that these receptors may have therapeutic uses, particularly for breast and prostate malignancies [62].

Free Radicals:

Free radicals are atoms or molecules that can give electrons to nearby molecules because of their unpaired electrons. Examples of these include nitric oxide (NO), hydroxyl ions (OH), superoxide (O2), and molecular oxygen (O2) [63]. Alcoholic hepatitis, organ transplants, hemodynamic shock, and inflammatory response all result in cellular damage due to these radicals. They can change their chemical surroundings by acting as electron acceptors or donors [63]. Superoxide radicals are produced by mitochondrial electron transport, which is the main way that free radicals cause inflammation. Furthermore, superoxide radicals are produced by the cyclooxygenase pathway's breakdown of arachidonic acid, which activates phospholipases and nonspecific proteases from increased intracellular calcium. This leads to the synthesis of eicosanoids like leukotrienes, prostaglandins, and thromboxanes, as well as pro-inflammatory mediators like platelet-activating factor (PAF) [64]. Studies demonstrate how cigarette smoke, which creates free radicals in the airway that cause inflammation and the release of proteases, contributes to lung damage. Since the generation of free radicals in inflammatory cells causes pathophysiological alterations, the ensuing airway inflammation may result in asthma. According to recent data, smoking causes leukocytes to emit more free radicals [65]. Many physiological processes are regulated by nitric oxide (NO). When L-arginine is converted to L-citrulline by nitric oxide synthase (NOs), physiological NO generation takes place. There are three main NOs isoforms: the calcium-independent iNOS/NOS2, which produces greater NO levels (micromolar range), endothelial NO synthase (eNOS/NOS3), and neuronal NO synthase (nNOS/NOS1), which are activated by calcium influx at nanomolar levels. [3], [66], and [67].

iNOS gene expression is substantially induced by inflammatory mediators such as lipopolysaccharide (LPS) and cytokines (e.g., IFN-γ), and isoform activation depends on calmodulin (CaM) binding. While iNOS stays active after expression, CaM binds to nNOS and eNOS via Ca2+ influx, producing prolonged non-physiological NO levels for host defense or cellular injury through changes in proliferation and mitochondrial activity that trigger apoptosis [68], [69]. Within biological systems, the hydroxyl radical (OH) is extremely reactive and easily forms in situ bonds with metals and other radicals. Because OH is reactive, it can interact with DNA to change purine and pyrimidine bases, which can result in gene mutations or inactivation. By oxidizing sulfhydryl groups and disulfide bonds, hydroxyl radicals can potentially damage proteins and enzymes found in cell membranes [70], [71]. When monocytes, neutrophils, macrophages, and eosinophils are activated, the superoxide radical (O2-), which is produced by electron gain in molecular oxygen, is especially formed. Lastly, molecular oxygen (O2) is essential to many biological functions, even though it is only moderately reactive in aqueous solutions [72]. Secondary biological harm from O2-has been documented. Its production is advantageous in situations such as bacterial infections, where enhanced neutrophil production aids in pathogen clearance, despite the fact that it is frequently linked to disease [73].

Histamine:

Histamine, a biogenic amine discovered by Dale and Laidlaw in 1910, is an essential molecule in

numerous biological processes, including inflammation and allergy responses. Originally recognized for its role as a potent uterine stimulant, histamine was later identified as a mediator of anaphylactic reactions in 1932 and has since become a widely studied molecule in cellular and molecular biology from histidine through decarboxylation, a process catalyzed by the enzyme L-histidine decarboxylase (HDC) with the cofactor pyridoxal 5'-phosphate (PLP) . Stored in the grasophils, mast cells, platelets, lymphocytes, and neurons, histamine is released upon stimulation to act on its four G-protein-coupled receptors: HR1, HR2, HR3, and HR4 . Histamine is metabolized with mo pathways. Through N-methyltransferase, it is converted to N-methyl-histamine, which monoamine oxidase further metabolizes to N-methyl imidazole acetic acid. Alternatively, it may undergo conversion to imidazole acetic acid by diamine oxidase (DAO), followed by conjugation to form imidazole ribose acetic acid . These pathways, particularly DAO in event excessive dietary histamine from entering circulation, maintaining systemic balance.

Histamine's effects are mediated by four receptor subtypes, each with distinct roles in the body:

- **H1 receptors**: Located in the central nervous system, vascular smooth muscle, airways, and various immune cells, H1 receptors control post-synaptic histamine effects. They stimulate inositol phospholipid signaling, leading to increased intracellular calcium and activating pathways that regulate inflammatory responses.
- **H2 receptors**: These receptors are found in several organs and notably influence gastric acid secretion by activating adenylate cyclase and increasing cyclic AMP levels. This mechanism, along with gastrin release, regulates the acid secretion process, important for digestion .
- **H3 receptors**: Primarily in neurons and cee cells, H3 receptors modulate histamine and neurotransmitter release and decrease cyclic AMP levels, affecting energy and food intake, with H3 receptor deficiencies linked to obesity and insulin resistance in studies .
- **H4 receptors**: Located in bone marrow and hematopoiethese receptors stimulate eosinophil and mast cell chemotaxis, impacting immune response, particularly in allergic inflammation .

Histamine also plays roles in immune modulation and cancer. It is cancer due to excessive HDC expression, although its exact influence on tumor development remains unclear. Additionally, it mediates allergic-inflammatory responses by stimulating cytokine and chemokine production, affecting eosinophil migration differently depending on concentration, thus modulating allergic inflammation at varying levels [74-82].

Cell Adhesion Molecules (CAMs):

Cell adhesion molecules (CAMs) are ns on the cell surface that facilitate contact between cells or between cells and the extracellular matrix, crucial for biological events like morphogenesis, immune response, and inflammation. CAMs play vital roles in immune cell recruitment and migration to inflammatory sites, with expression regulated by cytokines and other mediators . CAMs are categorized into three main groups based on molecular features:

- Selectincyte, platelet, and endothelium interactions, selectins (P, E, and L-selectin) mediate initial stages of cell recruitment during inflammation. For instance, P-selectin, expressed on endothelial cells and platelets, promotes inflammation, while E-selectin supports neutrophil and T cell adhesion to inflammatory sites .
- **Integrins**: Comprised of α and β subunits, integrins are transmembrane proteins connecting cells to molecules that participate in the inflammatory response and have been implicated in cancer metastasis by enabling cancer cell adhesion and migration, contributing to tumor progression and aggression .
- **Immunoglobulin Superfamily**: This class includes a range of adhesion molecules such as ICAM-1, ICAM-2, VCAM-1, and PECAM-1, which immune cell migration to inflamed areas .

Research on CAMs has highlighted their role in metastasis. Selectins, particularly P- and E-selectin, facilitate cancer cell migration to metastatic sites, while intell interactions within the microenvironment, furthering cancer progression . In inflammatory diseases, certain integrin subunits target leukocyte recruitment, offering potential therapeutic targets for treatment .

Other Mediators:

Arachidonic acid is the source of leukotrienes and prostaglandins, two substances that are essential for inflammatory reactions. There are two forms of

leukotrienes, which are mostly produced in leukocytes through the 5-lipoxygenase pathway: dihydroxy leukotrienes, such as LTB4, and cysteinyl leukotrienes, such as CysLTs. 5-lipoxygenase-activated LTB4 affects immunological processes such as neutrophil activation and interleukin-6 synthesis. It also interacts with receptors BLT1 and BLT2, which control intracellular calcium levels to promote cellular chemotaxis. Research on leukotriene inhibitors to treat asthma and allergic reactions has been prompted by the discovery that cystosLTs, which are found in mast cells and macrophages, induce vasodilation and are linked to asthma. Cyclooxygenase (COX) enzymes produce prostaglandins, which have hormone-like effects on inflammation and homeostasis. Prominent prostaglandins include prostacyclin (PGI2), which is necessary for vascular maintenance and gastric protection; thromboxanes, which are important for cardiovascular modulation and bronchoconstriction; PGD2, which encourages vasodilation and bronchoconstriction; PGE2, which increases vascular permeability; and PGF2α, which is important for reproductive processes. These substances function via G-protein-coupled receptors (GPCRs), where tissue- and cell-type-specific responses are mediated by variants such as DP, EP, and FP receptors. Prostaglandins are involved in pathological processes like cancer, ulcer development, and immunological suppression; PGE2 is particularly connected to immunosuppression by its effects on TH1 cell differentiation and cAMP. Furthermore, the three activation pathways—classical, alternative, and lectin—that make up the complement system, a proteolytic cascade essential to immunity, all converge on the cleavage of C3 and then C5 to create the membrane attack complex (MAC), which lyses pathogens. This system's regulation keeps the balance between immunological defense and self-tolerance by preventing harm to host tissues. Leukotrienes, prostaglandins, and the complement system work together to show how intricate the body's immunological and inflammatory responses are.

Role of Nursing in Inflammatory Disorders:

Nurses play an essential role in managing inflammatory disorders, integrating clinical skills with patient-centered care to mitigate symptoms, improve outcomes, and enhance quality of life for individuals affected by these conditions. This role encompasses assessment, education, intervention, and support. Nurses are responsible for comprehensive assessments, identifying signs and symptoms of inflammation, such as pain, swelling, and impaired mobility, and monitoring changes in a patient's condition. They coordinate and administer treatments, including pharmacological interventions like anti-inflammatory medications, and collaborate with interdisciplinary teams to optimize care strategies tailored to the patient's needs. Education is another vital component of nursing care in inflammatory disorders. Nurses provide patients and families with knowledge about disease processes, symptom management, medication adherence, and lifestyle modifications to reduce inflammation. This education empowers patients to participate actively in their care, promoting self-management strategies that include dietary adjustments, exercise, stress reduction, and proper rest.

Nurses also implement evidence-based interventions to alleviate symptoms and prevent complications. For example, in patients with rheumatoid arthritis or other chronic inflammatory conditions, nurses may apply joint protection techniques, assistive devices, and physical therapy exercises to enhance mobility and reduce strain on affected areas. They also play a critical role in infection prevention, recognizing that inflammation often compromises immune function, and they ensure that patients receive necessary immunizations and follow protocols to reduce infection risks. Emotional support is fundamental in nursing care for inflammatory disorders, as these conditions often lead to chronic pain, fatigue, and mental health challenges. Nurses assess and address psychosocial needs, connecting patients with counseling services and support groups, which can provide coping strategies and reduce feelings of isolation. Nurses engage in continuous professional development, staying current with advancements in treatments and technologies that may improve patient care. This commitment to lifelong learning ensures that nurses can deliver high-quality, holistic care to individuals with inflammatory disorders, thereby reducing the burden of these diseases and fostering better health outcomes across populations.

Conclusion:

This study underscores the critical role that nursing professionals play in managing inflammatory disorders through a nuanced understanding of the biochemical mechanisms underlying inflammation. By examining key signaling pathways—namely, NFκB, MAPK, and JAK-STAT—and their associated

mediators such as histamine, free radicals, and cell adhesion molecules, nurses gain insights into the physiological basis of inflammation. This biochemical knowledge is essential not only for understanding the progression of inflammatory diseases but also for enabling nurses to deliver tailored, evidence-based interventions. The integration of molecular insights into clinical practice empowers nurses to implement proactive care strategies. This includes early detection of inflammatory markers, precise administration of anti-inflammatory therapies, and timely patient education on lifestyle modifications that can mitigate inflammation. Furthermore, an informed nursing approach to monitoring patients can significantly reduce complications associated with chronic inflammation, enhancing the overall quality of patient outcomes. As inflammation is implicated in various chronic and acute health conditions, such as cardiovascular diseases, autoimmune disorders, and infections, the ability of nurses to interpret biochemical cues is invaluable for comprehensive care. Therefore, promoting continuous education in biochemistry and inflammation-related physiology for nursing professionals is recommended. Enhanced training in these areas would foster advanced competencies that support the increasingly complex landscape of patient needs. In conclusion, a deepened focus on the biochemical basis of inflammatory responses within nursing practice has the potential to transform patient care. By bridging molecular science with bedside care, nurses can contribute to improved treatment efficacy, reduced hospitalization rates, and better health management strategies for patients dealing with inflammatory disorders. As research on inflammation continues to evolve, incorporating these findings into nursing practice will remain essential to advancing healthcare outcomes.

References:

1. Ginwala, R., & Bhavsar, R. (2019). Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. *Antioxidants, 8*(2).
2. Kumar, R., Saha, N., & Purohit, P. (2019). Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. *European Journal of Medicinal Chemistry, 182*.
3. Da Silva, P., do Espírito Santo, R., & Melo, C. (2022). The compound (E)-2-Cyano-N,3-diphenylacrylamide (JMPR-01): A potential drug for treatment of inflammatory diseases. *Pharmaceutics, 14*(1).
4. Medzhitov, R. (2008). Origin and physiological roles of inflammation. *Nature, 454*, 428–435.
5. Takeuchi, O., & Akira, S. (2010). Pattern recognition and inflammation. *Cell, 140*, 805–820.
6. Chen, L., Deng, H., & Cui, H. (2017). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget, 9*(6).
7. Abdulkhaleq, L., Assi, M., Abdullah, R., Zamri-Saad, M., YH, T.-Y., & MNM, H. (2018). The crucial roles of inflammatory mediators in inflammation: A review. *Veterinary World, 11*(5).
8. Tu, H., & Li, Y. (2023). Inflammation balance in skeletal muscle damage and repair. *Frontiers in Immunology, 14*.
9. Ikeoka, D., Mader, J. K., & Pieber, T. R. (2010). Adipose tissue, inflammation and cardiovascular disease. *Associação Médica Brasileira, 56*, 116–121.
10. Tarek, H., Cho, S., Hossain, M., & Yoo, J. (2023). Attenuation of oxidative damage via upregulating Nrf2/HO-1 signaling pathway by protease SH21 with exerting anti-inflammatory and anticancer properties in vitro. *Cells, 12*(17).
11. Bekassy, Z., Lopatko, F. I., & Bader, M. (2022). Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. *Nature Reviews Immunology, 22*(7).
12. Kulinsky, V. (2007). Biochemical aspects of inflammation. *Biochemistry (Moscow), 72*, 595–607.
13. Perez, J. M. R., & Ruiz, J. M. M. (2012). A review: Inflammatory process in Alzheimer's disease, role of cytokines. *The Scientific World Journal*, Article 756357.
14. Rajeev, V., Fann, D., Dinh, Q., Kim, H., & De Silva, T. (2022). Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. *Theranostics, 12*(4).
15. Wang, B., Wu, L., Chen, J., Dong, L., & Chen, C. (2021). Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. *Signal Transduction and Targeted Therapy, 6*(1).
16. Ashina, K., Tsubosaka, Y., Nakamura, T., & Omori, K. (2015). Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo. *PLOS ONE, 10*(7).
17. Nunes, C. R., & Abreu, A. M. O. W. (2012). Influência dos radicais livres e envolvimento do processo inflamatório na aterosclerose. *Vértices, 14*, 53–69.

18. Rajesh, A., Rajesh, P., Pankaj, & Vijay, K. (2014). A brief cause of acute inflammation: An overview. *Journal of Drug Discovery and Therapeutics, 2*, 31–35.
19. Kumar, V., Abbas, A. K., & Aster, M. D. (2012). *Robbins Basic Pathology* (9th ed.). Elsevier.
20. Miller, S. B. (2006). Prostaglandins in health and disease: An overview. *Seminars in Arthritis and Rheumatism, 36*, 37–49.
21. Abbas, A. K., Lichtman, A. H., & Pillai, S. (2011). Imunologia Celular e Molecular (7th ed.). Elsevier.
22. Herwald, H., & Egesten, A. (2019). Tackling the pros and cons of inflammation. Journal of Innate Immunity, 11(6).
23. Netea, M., Domínguez-Andrés, J., & Barreiro, L. (2020). Defining trained immunity and its role in health and disease. Nature Reviews Immunology, 20(6).
24. Amarante-Mendes, G., Adjemian, S., Branco, L., Zanetti, L., W. R., & B. KR. (2018). Pattern recognition receptors and the host cell death molecular machinery. Frontiers in Immunology, 9.
25. Kubelkova, K., Bostik, V., Joshi, L., & Macela, A. (2023). Innate immune recognition, integrated stress response, infection, and tumorigenesis. Biology, 12(4).
26. Szukiewicz, D. (2023). Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity. International Journal of Molecular Sciences, 24(12).
27. Sun, H., Hu, W., Yan, Y., & Zhang, Z. (2021). Using PAMPs and DAMPs as adjuvants in cancer vaccines. Human Vaccines & Immunotherapeutics, 17(12).
28. Piccinini, A., & Midwood, K. (2010). DAMPening inflammation by modulating TLR signalling. Mediators of Inflammation, 2010.
29. Ishijima, T., & Nakajima, K. (2021). Inflammatory cytokines TNFα, IL-1β, and IL-6 are induced in endotoxin-stimulated microglia through different signaling cascades. Scientific Progress, 104(4).
30. Hu, X., Li, J., Fu, M., Zhao, X., & Wang, W. (2021). The JAK/STAT signaling pathway: From bench to clinic. Signal Transduction and Targeted Therapy, 6(1).
31. Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017). NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy, 2(1), 1–9.
32. Hinz, M., & Scheidereit, C. (2014). The IκB kinase complex in NF-κB regulation and beyond. EMBO Reports, 15(1).
33. Jubaidi, F., Zainalabidin, S., Taib, I., & Abdul Hamid, Z. (2022). The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications. International Journal of Molecular Sciences, 23(15).
34. Gur-Arie, L., Eitan-Wexler, M., Weinberger, N., & Rosenshine, I. (2020). The bacterial metalloprotease NleD selectively cleaves mitogen-activated protein kinases that have high flexibility in their activation loop. Journal of Biological Chemistry, 295(28).
35. Mohanta, T., Arora, P., Mohanta, N., Parida, P., & Bae, H. (2015). Identification of new members of the MAPK gene family in plants shows diverse conserved domains and novel activation loop variants. BMC Genomics, 16(1).
36. Harrison, D. (2012). The Jak/STAT pathway. Cold Spring Harbor Perspectives in Biology, 4(3).
37. Caveney, N., Saxton, R., Waghray, D., Glassman, C., & Tsutsumi, N. (2023). Structural basis of Janus kinase trans-activation. Cell Reports, 42(3).
38. Jarczak, D., & Nierhaus, A. (2022). Cytokine storm-definition, causes, and implications. International Journal of Molecular Sciences, 23(19).
39. Grunnet, L. G., & Mandrup-Poulsen, T. (2011). Cytokines and type 1 diabetes: A numbers game. Diabetes, 60, 697–699.
40. Laskin, D. L. (2009). Macrophages and inflammatory mediators in chemical toxicity: A battle of forces. Chemical Research in Toxicology, 22, 1376–1385.
41. Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014). Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1843(12), 2563–2582. https://doi.org/10.1016/j.bbamcr.2014.06.014
42. Camargo, A. E. I., Fujita, T. C., Lima, K. W., Aoki, M. N., & Watanabe, M. A. E. (2011). Envolvimento das quimiocinas CCL2 e CCL5 na patogênese do câncer de mama. Revista Brasileira de Análises Clínicas, 43, 116–120.
43. Balkwill, F. (2012). Chemokine system and cancer. Journal of Pathology, 226(2), 148–157. https://doi.org/10.1002/path.2995
44. Guerreiro, R., Santos, Q. C., & Azevedo, J. M. P. (2011). As quimiocinas e os seus receptores: Características e funções fisiológicas. Acta Médica Portuguesa, 24, 967–976.
45. Roshani, R., McCarthy, F., & Hagemann, T. (2014). Inflammatory cytokines in human

pancreatic cancer. Cancer Letters, 345(2), 157–163. https://doi.org/10.1016/j.canlet.2013.10.027
46. Grande, M. T., Pérez-Barriocanal, F., & López-Novoa, J. M. (2010). Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy. Journal of Inflammation, 7, 19. https://doi.org/10.1186/1476-9255-7-19
47. Lobo, M. R. G., Furatdo, S. C., & Júnior, J. R. D. (2014). Citocinas na dengue: Inovações do sistema imune. Sci. Amazon, 3, 25–40.
48. Sena, L., Loureiro, D., Sousa, T. J., Meyer, R., & Portelas, R. W. (2012). Quimiocinas e sua importância na infecção por Mycobacterium tuberculosis. Revista de Ciências Médicas e Biológicas, 11, 326–333.
49. Renne, T., Schmaier, A. H., Nickel, K. F., Blombä, M., & Mass, C. (2012). In vivo roles of factor XII. Blood, 120(21), 4296–4303. https://doi.org/10.1182/blood-2012-04-420928
50. Kenne, E., & Renne, T. (2014). Factor XII: A drug target for safe interference with thrombosis and inflammation. Drug Discovery Today, 19(10), 1459–1464. https://doi.org/10.1016/j.drudis.2014.04.008
51. Sharma, J. N., & AL-Sherif, G. J. (2011). The kinin system: Present and future pharmacological targets. American Journal of Biomedicine and Sciences, 3(3), 156–169. https://doi.org/10.5099/ajbms.3.3.156
52. Bujak-Giżycka, B., Olszanecki, R., Madej, J., Suski, M., Gębska, A., & Korbut, R. (2011). Metabolism of bradykinin in aorta of hypertensive rats. Acta Biochimica Polonica, 58(2), 199–202.
53. Maurer, M., Bader, M., Bas, M., Bossi, M., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb-Lundberg, F., Lötvall, J., & Magerl, M. (2011). New topics in bradykinin research. Allergy, 66(11), 1397–1406. https://doi.org/10.1111/j.1398-9995.2011.02733.x
54. Sharma, J. N. (2014). Basic and clinical aspects of bradykinin receptor antagonists. Progress in Drug Research, 69, 1–14.
55. Chao, J., Bledsoe, G., & Chao, L. (2014). Tissue kallikrein-kinin therapy in hypertension and organ damage. Progress in Drug Research, 69, 37–57.
56. Kashuba, E., Bailey, J., Allsup, D., & Cawkwell, L. (2013). The kinin–kallikrein system: Physiological roles, pathophysiology, and its relationship to cancer biomarkers. Biomarkers, 18(3), 279–296. https://doi.org/10.3109/1354750X.2013.771209
57. Lin, K. S., Pan, J., Amouroux, G., Turashvili, G., Mesak, F., Hundal-Jabal, N., Pourghiasian, M., Lau, J., Jenni, S., Aparicio, S., Bénard, F. (2015). In vivo radioimaging of bradykinin receptor B1, a widely overexpressed molecule in human cancer. Cancer Research, 75(2), 387–393. https://doi.org/10.1158/0008-5472.CAN-14-2785
58. Bhat, M., Pouliot, M., Couture, R., & Vaucher, E. (2014). The kallikrein-kinin system in diabetic retinopathy. Progress in Drug Research, 69, 111–143.
59. Naffah-Mazzacoratti, M. G., Gouveia, T. L. F., Simões, P. S. R., & Perosa, S. R. (2014). What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders? World Journal of Biological Chemistry, 5(3), 130–140. https://doi.org/10.4331/wjbc.v5.i3.130
60. Ehrenfeld, P., Manso, L., Pavicic, M. F., Matus, C. E., Borquez, C., Lizama, A., Sarmiento, J., Poblete, M. T., Bhoola, K. T., Naran, A., & Figueroa, C. D. (2014). Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the Kinin B1 receptor in breast cancer cells. Anticancer Research, 34(12), 6925–6938.
61. Costa, P. L. N., Sirois, P., Tannock, I. F., & Chammas, R. (2014). The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters, 345(1), 27-38. https://doi.org/10.1016/j.canlet.2013.11.014
62. Sgnaolin, V., Pereira, T. C. B., Bogo, M. R., Zanin, R., Battastini, A. M. O., Morrone, F. B., & Campos, M. M. (2013). Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: Implication of the PI3Kg pathway. Investigational New Drugs, 31(4), 812-822. https://doi.org/10.1007/s10637-013-9920-2
63. Martelli, F., & Nunes, F. M. F. (2014). Radicais livres: Em busca do equilíbrio. Ciência & Cultura, 66(1), 54-57.
64. Miguel, M. P., Menezes, L. B., & Araújo, E. G. (2012). Fisiopatologia do estresse oxidativo após isquemia e repercussão cerebral e potencial neuroproteção do pequi (Caryocar brasiliense). Enciclopédia Biosfera, 8, 1961.
65. Vasconcelos, T. B., Cardoso, A. R. N. R., Josino, J. B., Macena, R. H. M., & Bastos, V. P. D. (2014). Radicais livres e antioxidantes: Proteção ou perigo? UNOPAR Científica Ciências Biológicas e da Saúde, 16(2), 213-219.
66. Król, M., & Kepinska, M. (2020). Human nitric oxide synthase-its functions, polymorphisms, and inhibitors in the context of inflammation, diabetes and cardiovascular diseases. International Journal of Molecular Sciences, 22(1), 88. https://doi.org/10.3390/ijms22010088

67. Cruz, R. M. D., Braga, R. M., Andrade, H. H. N. de, Monteiro, Á. B., Luna, I. S., & da Cruz, R. M. D. (2020). RMD86, a thiophene derivative, promotes antinociceptive and antipyretic activities in mice. Heliyon, 6(11), e05550. https://doi.org/10.1016/j.heliyon.2020.e05550
68. Hu, X., Li, J., Fu, M., Zhao, X., & Wang, W. (2021). The JAK/STAT signaling pathway: From bench to clinic. Signal Transduction and Targeted Therapy, 6(1), 1-21. https://doi.org/10.1038/s41392-021-00616-z
69. Roh, J., & Sohn, D. (2018). Damage-associated molecular patterns in inflammatory diseases. Immune Network, 18(4), e22. https://doi.org/10.4110/in.2018.18.e22
70. Halliwell, B. (2012). Free radicals and antioxidants: Updating a personal view. Nutritional Reviews, 70(5), 257-265. https://doi.org/10.1111/j.1753-4887.2012.00459.x
71. Maia, M. S., & Bicudo, S. D. (2009). Radicais livres, antioxidantes e função espermática em mamíferos: Uma revisão. Revista Brasileira de Reprodução Animal, 33(3), 183-193.
72. Almeida, C. (2014). Alterações no estado oxidativo salivar em indivíduos com disfunção temporomandibular. Retrieved from http://dspace.c3sl.ufpr.br/dspace/bitstream/handle/1884/35638/R%20-%20D%20-%20CLAUDYANE%20DE%20ALMEIDA.pdf?sequence=1
73. Pereira, B. C., & Pereira, A. K. F. T. (2012). Radicais livres: Uma nova abordagem. Revista Saúde Quântica, 1(1), 35-42.
74. Criado, P. R., Criado, R. F. J., Maruta, C. W., & Machado, F. C. A. (2010). Histamina: Receptores de histamina e anti-histamínicos: Novos conceitos. Brasilian Journal of Dermatology, 85(3), 195-210.
75. Mahdy, A. M., & Webster, N. R. (2014). Histamine and antihistamines. Anaesthesia & Intensive Care Medicine, 15(5), 250-255. https://doi.org/10.1016/j.mpaic.2014.02.002
76. Akdis, C. A., & Blaser, K. (2003). Histamine in the immune regulation of allergic inflammation. Journal of Allergy and Clinical Immunology, 112(1), 15-22. https://doi.org/10.1016/S0091-6749(03)00430-2
77. Jutel, M., Watanabe, T., Akdis, M., Blaser, K., & Akdis, C. (2002). Immune regulation by histamine: Opinion. Current Opinion in Immunology, 14(6), 735-740. https://doi.org/10.1016/S0952-7915(02)00391-0
78. Longo, D. L., & Fauci, A. S. (2014). Gastroenterologia e Hepatologia de Harrison (2nd ed.). McGraw-Hill.
79. Katzung, B. G., Masters, S. B., & Trevor, A. J. (2014). Farmacologia Básica e Clínica (12th ed.). McGraw-Hill.
80. Simons, F. E. R., & Simons, K. J. (2011). Histamine and H1-antihistamines: Celebrating a century of progress. Journal of Allergy and Clinical Immunology, 128(6), 1139-1150. https://doi.org/10.1016/j.jaci.2011.10.009
81. Hu, J., Gao, J., Wang, C., Liu, W., Hu, A., & Xiao, X. (2023). FLI1 regulates histamine decarboxylase expression to control inflammation signaling and leukemia progression. Journal of Inflammation Research, 16, 801-814. https://doi.org/10.2147/JIR.S340412
82. Akdis, C. A., & Simons, F. E. R. (2006). Histamine receptors are hot in immunopharmacology. European Journal of Pharmacology, 533(1-3), 69-76. https://doi.org/10.1016/j.ejphar.2005.12.046
83. Gomes, M. A. M., Neto, N. C. M., & Bispo, I. G. A. (2009). Interleucina-6, moléculas de adesão intercelular-1 e microalbuminúria na avaliação da lesão endotelial: Revisão de literatura. Revista SOCERJ, 22(6), 398-403.
84. Makrilia, N., Kollias, A., Manolopoulos, L., & Syrigos, K. (2009). Cell adhesion molecules: Role and clinical significance in cancer. Cancer Investigation, 27(10), 1023-1037. https://doi.org/10.1080/07357900903110810